Wilms' tumor 1 as a novel target for immunotherapy of leukemia.
Wilms' tumor 1 (WT1) is a leukemia associated antigen (LAA) differentially expressed by leukemic blasts. Thus, WT1 may constitute a target for therapies such as those mediated by adoptive-specific T lymphocytes. Serological and cellular immune responses have been elicited by WT1 in patients with leukemia. Specific CD8+ T cells able to recognize this antigen can be selected by streptamers and then infused into leukemia patients. Potentially, these T cells could lyse leukemic blasts expressing WT1. The only good manufacturing practice-certified technology is streptamers, which are available for antigen-specific T-cell sorting. Immunocompromised patients may have their antigen-specific immune responses restored through the transfer of adoptive T cells specific for this LAA.
Department of Internal Medicine III, University Clinic Rostock, Rostock, Germany.
R
R
Casalegno-Garduño
A
A
Schmitt
X
X
Wang
X
X
Xu
M
M
Schmitt
D019264:Adoptive Transfer; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D018797:Cell Cycle Proteins; D006801:Humans; D007167:Immunotherapy; D007938:Leukemia / Q000628:therapy*; D009687:Nuclear Proteins / Q000276:immunology*; D000072260:RNA Splicing Factors
D018797:Cell Cycle Proteins; D009687:Nuclear Proteins; D000072260:RNA Splicing Factors; C419554:WTAP protein, human